Kezar Life Sciences, Inc (KZR)

Etorro trading 970x250
Kezar Life Sciences, Inc (KZR) Logo

About Kezar Life Sciences, Inc

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California. Address: 4000 Shoreline Court, South San Francisco, CA, United States, 94080

Kezar Life Sciences, Inc News and around…

Latest news about Kezar Life Sciences, Inc (KZR) common stock and company :

10 Pharmaceutical Stocks to Buy According to Lawrence Hawkins’ Prosight Capital
15 Oct, 2021 Yahoo! Finance

In this article, we discuss 10 pharmaceutical stocks to buy according to Lawrence Hawkins’ Prosight Capital. If you want to skip our detailed analysis of Hawkins’ history, investment philosophy, and hedge fund performance, go directly to the 5 Pharmaceutical Stocks to Buy According to Lawrence Hawkins’ Prosight Capital. Lawrence Hawkins, the managing partner of Dallas-based […]

Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs
05 Oct, 2021 FinancialContent

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Gitanjali Jain as Vice President, Investor Relations and External Affairs. As a member of the management team and executive committee, Ms. Jain will lead Kezar’s overall investor relations, public relations, and scientific communications efforts.

3 Hot Growth Stocks to Beat the Market Volatility
21 Sep, 2021 Yahoo! Finance

Volatility is back on the menu. U.S. stocks began the week deeply in the red as investors grappled with a number of risks, including a possible shift in Federal Reserve guidance this week that could hurt corporate profits. There are also concerns that Evergrande - a major Chinese property developer - could default on its hundreds of billions in debt and trigger a financial crisis beyond China. The key to success in this environment is really the same as in ‘normal’ times. Look for stocks with so

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

46 Biggest Movers From Yesterday
15 Sep, 2021 FinancialContent

Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
14 Sep, 2021 FinancialContent

Gainers Progenity (NASDAQ:PROG) shares increased by 17.0% to $1.1 during Tuesday's regular session. As of 12:30 EST, ...

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
09 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
03 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
02 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
02 Sep, 2021 FinancialContent

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in the following upcoming virtual investor conferences:

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
01 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
31 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis
23 Aug, 2021 FinancialContent

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that PRESIDIO, its Phase 2 clinical trial to evaluate the safety and efficacy of KZR-616 for the treatment of polymyositis (PM) and dermatomyositis (DM) completed the target enrollment of 24 subjects.

Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates
12 Aug, 2021 FinancialContent

Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its second quarter 2021 financial results and corporate highlights.

Kezar Life Sciences is Now Oversold (KZR)
03 Aug, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

The Math Shows VTWV Can Go To $164
03 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $163.71 per unit.

Could The Kezar Life Sciences, Inc. (NASDAQ:KZR) Ownership Structure Tell Us Something Useful?
26 Jul, 2021 Yahoo! Finance

If you want to know who really controls Kezar Life Sciences, Inc. ( NASDAQ:KZR ), then you'll have to look at the...

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021
20 Jul, 2021 FinancialContent

Upgrades For Bank of Marin Bancorp (NASDAQ:BMRC), Keefe, Bruyette & Woods upgraded the previous rating of Market ...

KZR Crosses Above Key Moving Average Level
08 Jul, 2021 FinancialContent

In trading on Thursday, shares of Kezar Life Sciences Inc (KZR) crossed above their 200 day moving average of $5.65, changing hands as high as $5.66 per share. Kezar Life Sciences Inc shares are currently trading up about 3.1% on the day..

Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021
08 Jul, 2021 FinancialContent

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Co-founder and Chief Scientific Officer, Christopher Kirk, will participate in the “Novel Targets for Autoimmune Diseases” panel discussion at William Blair's Biotech Focus Conference on Thursday, July 15, 2021, at 11:00 a.m. ET.

Analysts Forecast 21% Upside For IBBQ
01 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $31.25 per unit.

Kezar Life Sciences Announces Formation of Clinical Advisory Committee
08 Jun, 2021 FinancialContent

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the formation of its Clinical Advisory Committee.

12 Health Care Stocks Moving In Wednesday's After-Market Session
02 Jun, 2021 FinancialContent

Gainers Tilray (NASDAQ:TLRY) shares increased by 4.05% to $19.77 during Wednesday's after-market session. This security traded at a ...

The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements
02 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021
02 Jun, 2021 FinancialContent

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported results from the completed Phase 1b dose escalation portion of its MISSION study, evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in systemic lupus erythematosus (SLE) patients with and without nephritis. The data are being presented by Richard Furie, M.D., Chief of Division of Rheumatology at Northwell Health in New York, in a poster session at EULAR, the Annual European Congress of Rheumatology, being held virtually from June 2 to 5, 2021. The poster can be found on Kezar’s website under the “Our Science” section.

Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors
01 Jun, 2021 FinancialContent

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Micki Klearman, M.D. to its Board of Directors.

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
31 May, 2021 FinancialContent

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May ...

Kezar Life Sciences to Participate in the Jefferies Virtual Healthcare Conference
27 May, 2021 FinancialContent

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 2:00 p.m. ET.

Kezar Life Sciences to Host Virtual MISSION Phase 1b Data Update Call at EULAR 2021 on June 2, 2021
26 May, 2021 FinancialContent

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a MISSION Phase 1b data update call for investors and analysts during the European Congress of Rheumatology (EULAR 2021) on Wednesday, June 2, 2021 at 4:30 p.m. ET.

Kezar Life Sciences, Inc (KZR) is a NASDAQ Common Stock listed in , ,

970x250